← Eichor
Study identifier: NCT05692024 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

COffee and Metabolites Modulating the Gut MicrobiomE in Colorectal caNCER

Condition: Colorectal Cancer · Coffee · Gastrointestinal Microbiome  ·  Sponsor: Massachusetts General Hospital

PhasePhase 1/Phase 2
Planned participants80
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This is research study is assessing the effects of 6-g daily use of freeze-dried instant coffee on liver fat and fibrosis and the gut microbiome and metabolome in patients who have completed routine treatment (including surgery, chemotherapy and radiotherapy) for stage I-III colorectal cancer.

This description comes directly from the study's public registry record.

Talk to the study team

Mingyang Song, MD, ScD  ·  (617) 643-3364  ·  msong2@mgh.harvard.edu

Aparna R Parikh, MD, MS  ·  (617) 726-4000  ·  APARNA.PARIKH@MGH.HARVARD.EDU

Always discuss trial participation with your own doctor first.

Locations (1)

Massachusetts General HospitalBoston, Massachusetts, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05692024